+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Heart Failure Market and Forecast Analysis to 2024

  • ID: 4462134
  • Report
  • 421 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Chronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmia's, but structural disorders of the heart muscle or valves are also common causes. While current therapies have helped to improve patient outcomes, CHF still remains a major public health issue and is associated with high mortality rates and a poor prognosis.

Market Snapshot
  • Increased use of Entresto and a full pipeline will revitalize the mature CHF market.
  • Novel CHF treatments have yet to alter prescribing practices from traditional ACE inhibitors and beta blockers.
  • CHF prevalence rises with age, with 55–84 years comprising three-quarters of all diagnosed prevalent cases in adults.
  • Entresto has overcome initial barriers to uptake and has the potential to change CHF treatment practices.
  • Despite a full pipeline it is unlikely that any candidates have the potential to significantly change treatment practices.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: CHRONIC HEART FAILURE
Overview
Executive Summary
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile (Late Stage): C-Cure
Product Profile: Corlanor
Product Profile: Entresto
Product Profile (Late Stage): Farxiga
Product Profile (Late Stage): Jardiance
Product Profile (Late Stage): Mpc-150-Im
Product Profile (Late Stage): Xarelto
Product Profile (Late Stage): Omecamtiv Mecarbil
Product Profile (Late Stage): Vericiguat

TREATMENT: CHRONIC HEART FAILURE (Published on 04 October 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends: Chf With Reduced Ejection Fraction
Prescribing Trends: Chf With Preserved Ejection Fraction
Compliance Rates

EPIDEMIOLOGY: CHRONIC HEART FAILURE (Published on 03 January 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: CHRONIC HEART FAILURE (Published on 11 December 2017)
Overview
Executive Summary
Product Overview
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Beta Blockers
Aldosterone Antagonists
Other Drug Classes
Product Profile: Corlanor
Product Profile: Entresto

CHRONIC HEART FAILURE PRICING, REIMBURSEMENT, AND ACCESS (Published on 13 April 2018)
Overview
Executive Summary
Regulatory Labels And Guidelines
Global Access Levers
Evidence And Value
Access To Recently Approved And Pipeline Products
Pricing
Us
Canada
France
Germany
Italy
Spain
Uk
Methodology

PIPELINE: CHRONIC HEART FAILURE (Published on 11 December 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): C-Cure
Product Profile (Late Stage): Farxiga
Product Profile (Late Stage): Jardiance
Product Profile (Late Stage): Mpc-150-Im
Product Profile (Late Stage): Xarelto
Product Profile (Late Stage): Omecamtiv Mecarbil
Product Profile (Late Stage): Vericiguat

LIST OF FIGURES
Figure 1: Chronic heart failure – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for chronic heart failure
Figure 3: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Sales of Jardiance and Farxiga in the US, Japan, and five major EU markets, 2017–26
Figure 6: Sales of generic ACE inhibitors and ARBs in the US, Japan, and five major EU markets, 2017–26
Figure 7: Sales of MPC-150-IM and C-Cure in the US, Japan, and five major EU markets, 2017–26
Figure 8: Sales of vericiguat and omecamtiv mecarbil in the US, Japan, and five major EU markets, 2017–26
Figure 9: Sales of Xarelto and rivaroxaban generics in the US, Japan, and five major EU markets, 2017–26
Figure 10: Chronic heart failure drug sales in the US, by class, 2017–26
Figure 11: Chronic heart failure drug sales in the five major EU markets, by country, 2017–26
Figure 12: Chronic heart failure drug sales in the five major EU markets, by class, 2017–26
Figure 13: Chronic heart failure drug sales in Japan, by class, 2017–26
Figure 14: Methodology flow for The authors chronic heart failure forecast
Figure 15: Price sources and calculations, by country
Figure 16: C-Cure for chronic heart failure – SWOT analysis
Figure 17: The authors drug assessment summary of C-Cure for chronic heart failure
Figure 18: The authors drug assessment summary of C-Cure for chronic heart failure
Figure 19: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Corlanor for chronic heart failure – SWOT analysis
Figure 21: The authors drug assessment summary of Corlanor for chronic heart failure
Figure 22: The authors drug assessment summary of Corlanor for chronic heart failure
Figure 23: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Entresto for chronic heart failure – SWOT analysis
Figure 25: The authors drug assessment summary of Entresto for chronic heart failure
Figure 26: The authors drug assessment summary of Entresto for chronic heart failure
Figure 27: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 28: Farxiga for chronic heart failure – SWOT analysis
Figure 29: The authors drug assessment summary of Farxiga for chronic heart failure
Figure 30: The authors drug assessment summary of Farxiga for chronic heart failure
Figure 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 32: Jardiance for chronic heart failure – SWOT analysis
Figure 33: The authors drug assessment summary of Jardiance for chronic heart failure
Figure 34: The authors drug assessment summary of Jardiance for chronic heart failure
Figure 35: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 36: MPC-150-IM for chronic heart failure – SWOT analysis
Figure 37: The authors drug assessment summary of MPC-150-IM for chronic heart failure
Figure 38: The authors drug assessment summary of MPC-150-IM for chronic heart failure
Figure 39: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 40: Xarelto for chronic heart failure – SWOT analysis
Figure 41: The authors drug assessment summary of Xarelto for chronic heart failure
Figure 42: The authors drug assessment summary of Xarelto for chronic heart failure
Figure 43: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 44: Omecamtiv mecarbil for chronic heart failure – SWOT analysis
Figure 45: The authors drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 46: The authors drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 47: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 48: Vericiguat for chronic heart failure – SWOT analysis
Figure 49: The authors drug assessment summary of vericiguat for chronic heart failure
Figure 50: The authors drug assessment summary of vericiguat for chronic heart failure
Figure 51: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 52: Diagnostic flow chart for patients with suspected heart failure
Figure 53: Percentage incidence of co-morbidities among chronic heart failure patients in the US, Japan, and five major EU markets, by co-morbidity/risk factor
Figure 54: Percentage of CHF patients across the US, Japan, and five major EU markets who are over the age of 65, diagnosed with hypertension, or diagnosed with CAD
Figure 55: Percentage of CHF patients diagnosed with HFrEF and HFpEF across the US, Japan, and five major EU markets, by country
Figure 56: Percentage of patients with HFrEF in each NYHA class, by country
Figure 57: Percentage of patients with HFpEF in each NYHA class, by country
Figure 58: Percentage of HFrEF patients receiving each treatment type, by NYHA class
Figure 59: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFrEF, by NYHA class and country
Figure 60: Percentage of regimens containing beta blockers for the first-line treatment of HFrEF, by NYHA class and country
Figure 61: Percentage of regimens containing ARBs for the first-line treatment of HFrEF, by NYHA class and country
Figure 62: Percentage of regimens containing ARBs for the treatment of HFrEF, by NYHA class and line of treatment
Figure 63: Percentage of regimens containing diuretics for the first-line treatment of HFrEF, by country and NYHA class
Figure 64: Percentage of regimens containing MRAs for the first-line treatment of HFrEF, by country and NYHA class
Figure 65: Percentage of regimens containing SGLT-2 inhibitors for the first-line treatment of HFrEF, by country and NYHA class
Figure 66: Percentage of regimens containing the SGLT-2 inhibitors Jardiance and Farxiga for the first-line treatment of HFrEF, by NYHA class
Figure 67: Top three drug regimens for first-line treatment of class I HFrEF, by country
Figure 68: Top three drug regimens for second-line treatment of class I HFrEF, by country
Figure 69: Top three drug regimens for first-line treatment of class II–III HFrEF, by country
Figure 70: Top three drug regimens for second-line treatment of class II–III HFrEF, by country
Figure 71: Top three drug regimens for first-line treatment of class IV HFrEF, by country
Figure 72: Top three drug regimens for second-line treatment of class IV HFrEF, by country
Figure 73: Percentage of HFpEF patients receiving each treatment type, by NYHA class
Figure 74: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFpEF, by NYHA class and country
Figure 75: Percentage of regimens containing ARBs for the first-line treatment of HFpEF, by NYHA class and country
Figure 76: Percentage of regimens containing beta blockers for the first-line treatment of HFpEF, by country and NYHA class
Figure 77: Percentage of regimens containing diuretics for the first-line treatment of HFpEF, by country and NYHA class
Figure 78: Percentage of regimens containing MRAs for the first-line treatment of HFpEF, by country and NYHA class
Figure 79: Top three drug regimens for first-line treatment of class I HFpEF, by country
Figure 80: Top three drug regimens for second-line treatment of class I HFpEF, by country
Figure 81: Top three drug regimens for first-line treatment of class II–III HFpEF, by country
Figure 82: Top three drug regimens for second-line treatment of class II–III HFpEF, by country
Figure 83: Top three drug regimens for first-line treatment of class IV HFpEF, by country
Figure 84: Top three drug regimens for second-line treatment of class IV HFpEF, by country
Figure 85: Compliance rates of chronic heart failure patients in the US, Japan, and five major EU markets, by country and ejection fraction
Figure 86: Trends in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
Figure 87: Corlanor for chronic heart failure – SWOT analysis
Figure 88: The authors drug assessment summary of Corlanor for chronic heart failure
Figure 89: The authors drug assessment summary of Corlanor for chronic heart failure
Figure 90: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 91: Entresto for chronic heart failure – SWOT analysis
Figure 92: The authors drug assessment summary of Entresto for chronic heart failure
Figure 93: The authors drug assessment summary of Entresto for chronic heart failure
Figure 94: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 95: European Society of Cardiology Heart Failure guidelines
Figure 96: American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines
Figure 97: Price sources and calculations for the US and EU, by country
Figure 98: C-Cure for chronic heart failure – SWOT analysis
Figure 99: The authors drug assessment summary of C-Cure for chronic heart failure
Figure 100: The authors drug assessment summary of C-Cure for chronic heart failure
Figure 101: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 102: Farxiga for chronic heart failure – SWOT analysis
Figure 103: The authors drug assessment summary of Farxiga for chronic heart failure
Figure 104: The authors drug assessment summary of Farxiga for chronic heart failure
Figure 105: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 106: Jardiance for chronic heart failure – SWOT analysis
Figure 107: The authors drug assessment summary of Jardiance for chronic heart failure
Figure 108: The authors drug assessment summary of Jardiance for chronic heart failure
Figure 109: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 110: MPC-150-IM for chronic heart failure – SWOT analysis
Figure 111: The authors drug assessment summary of MPC-150-IM for chronic heart failure
Figure 112: The authors drug assessment summary of MPC-150-IM for chronic heart failure
Figure 113: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 114: Xarelto for chronic heart failure – SWOT analysis
Figure 115: The authors drug assessment summary of Xarelto for chronic heart failure
Figure 116: The authors drug assessment summary of Xarelto for chronic heart failure
Figure 117: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 118: Omecamtiv mecarbil for chronic heart failure – SWOT analysis
Figure 119: The authors drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 120: The authors drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 121: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 122: Vericiguat for chronic heart failure – SWOT analysis
Figure 123: The authors drug assessment summary of vericiguat for chronic heart failure
Figure 124: The authors drug assessment summary of vericiguat for chronic heart failure
Figure 125: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 3: SGLT-2 inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Generic ACE inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Generic ARB sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Generic ACE inhibitor patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Table 7: Generic ARB patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Table 8: Stem cell therapy sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Stem cell therapy patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Table 10: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 11: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: Chronic heart failure drug sales across the US and five major EU markets, by country ($m), 2017–26
Table 14: Summary of drug classes and molecules included in The authors chronic heart failure patient-based forecast
Table 15: Exchange rates used for calculating prices
Table 16: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 17: C-Cure drug profile
Table 18: C-Cure proposed Phase III trial design in chronic heart failure
Table 19: C-Cure completed late-phase data in chronic heart failure
Table 20: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 21: Corlanor drug profile
Table 22: Corlanor pivotal Phase III trial data in chronic heart failure
Table 23: Corlanor Phase II trial data in chronic heart failure
Table 24: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 25: Entresto drug profile
Table 26: Entresto Phase III data in chronic heart failure
Table 27: Ongoing pivotal trials for Entresto in chronic heart failure
Table 28: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 29: Farxiga drug profile
Table 30: Farxiga Phase III trials in chronic heart failure
Table 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 32: Jardiance drug profile
Table 33: Jardiance Phase III trials in chronic heart failure
Table 34: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 35: MPC-150-IM drug profile
Table 36: MPC-150-IM late-phase trials in chronic heart failure
Table 37: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 38: Xarelto drug profile
Table 39: Xarelto Phase III data in chronic heart failure
Table 40: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 41: Omecamtiv mecarbil drug profile
Table 42: Omecamtiv mecarbil Phase III study in chronic heart failure
Table 43: Omecamtiv mecarbil Phase II data in chronic heart failure
Table 44: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 45: Vericiguat drug profile
Table 46: Vericiguat Phase III trials in chronic heart failure
Table 47: Vericiguat Phase II data in chronic heart failure
Table 48: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 49: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 50: Common laboratory test abnormalities in chronic heart failure
Table 51: Definitions of HFrEF and HFpEF
Table 52: New York Heart Association functional classification based on severity of symptoms and physical activity
Table 53: Comparison of ACCF/AHA stages of HF with NYHA functional classification
Table 54: Treatments available for chronic heart failure across the US, Japan, and five major EU markets
Table 55: NYHA functional classes I–IV, classification summary
Table 56: Sources used for the epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country
Table 57: Sources used for the previous epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country (published 9 October 2017)
Table 58: Diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
Table 59: Key marketed drugs for chronic heart failure
Table 60: Angiotensin-converting enzyme inhibitors class overview
Table 61: Angiotensin receptor blocker class overview
Table 62: Beta blocker class overview
Table 63: Aldosterone antagonists class overview
Table 64: Other drug class overview
Table 65: Corlanor drug profile
Table 66: Corlanor pivotal Phase III trial data in chronic heart failure
Table 67: Corlanor Phase II trial data in chronic heart failure
Table 68: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 69: Entresto drug profile
Table 70: Entresto Phase III data in chronic heart failure
Table 71: Ongoing pivotal trials for Entresto in chronic heart failure
Table 72: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 73: Regulatory labels for Entresto in the US, Japan, and five major EU markets
Table 74: Reimbursement restrictions for Entresto across the US and five surveyed EU markets
Table 75: Primary and secondary care prescribing of Entresto in the five major EU markets
Table 76: Use of efficiency audits for Entresto in the five major EU markets
Table 77: Payer concerns surrounding the Phase III PARADIGM-HF patient population
Table 78: Payer views on the primary and secondary endpoints used in the Phase III PARADIGM-HF trial
Table 79: Impact of reduction in CHF hospitalization for Entresto across the US and five major EU markets
Table 80: Impact of Entresto’s HRQoL benefits across the five major EU markets
Table 81: Benefits of Jardiance versus Entresto
Table 82: Pricing of Entresto in the US and five major EU markets, by country
Table 83: Formulary placement of Entresto in selected commercial formularies
Table 84: Formulary placement of Entresto in selected Medicare Part D formularies
Table 85: Prior authorization criteria for Entresto in eight major health plans
Table 86: CADTH assessment of Entresto
Table 87: Transparency Committee's ASMR ratings and pricing implications
Table 88: Transparency Committee's SMR ratings and pricing implications
Table 89: Transparency Committee's assessment of Entresto
Table 90: G-BA assessment of Entresto
Table 91: Reimbursement conditions for Entresto in Italy
Table 92: National and regional reimbursement decisions in Spain
Table 93: NICE assessment of Entresto
Table 94: SMC assessment of Entresto
Table 95: Exchange rates used for calculating branded drug prices
Table 96: Profiled pipeline products in development for chronic heart failure
Table 97: C-Cure drug profile
Table 98: C-Cure proposed Phase III trial design in chronic heart failure
Table 99: C-Cure completed late-phase data in chronic heart failure
Table 100: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 101: Farxiga drug profile
Table 102: Farxiga Phase III trials in chronic heart failure
Table 103: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 104: Jardiance drug profile
Table 105: Jardiance Phase III trials in chronic heart failure
Table 106: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 107: MPC-150-IM drug profile
Table 108: MPC-150-IM late-phase trials in chronic heart failure
Table 109: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 110: Xarelto drug profile
Table 111: Xarelto Phase III data in chronic heart failure
Table 112: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 113: Omecamtiv mecarbil drug profile
Table 114: Omecamtiv mecarbil Phase III study in chronic heart failure
Table 115: Omecamtiv mecarbil Phase II data in chronic heart failure
Table 116: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 117: Vericiguat drug profile
Table 118: Vericiguat Phase III trials in chronic heart failure
Table 119: Vericiguat Phase II data in chronic heart failure
Table 120: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4462134
Adroll
adroll